[In vivo efficacy of Ingavirin against pandemic A (H1N1/09)v influenza virus].
Shishkina
L N
LN
Nebol'sin
V E
VE
Skarnovich
M O
MO
Kabanov
A S
AS
Sergeev
A A
AA
Erdyneeva
U B
UB
Serova
O A
OA
Demina
O K
OK
Agafonov
A P
AP
Stavskiĭ
E A
EA
Drozdov
I G
IG
D000577:Amides / Q000627:therapeutic use*; D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use*; D002208:Caproates; D003998:Dicarboxylic Acids / Q000627:therapeutic use*; D005260:Female; D007093:Imidazoles / Q000627:therapeutic use*; D053118:Influenza A Virus, H1N1 Subtype / Q000187:drug effects* / Q000502:physiology; D053122:Influenza A Virus, H3N2 Subtype / Q000187:drug effects; D008168:Lung / Q000187:drug effects / Q000821:virology; D051379:Mice; D008807:Mice, Inbred BALB C; D009976:Orthomyxoviridae Infections / Q000188:drug therapy* / Q000401:mortality / Q000821:virology; D053139:Oseltamivir / Q000627:therapeutic use; D012299:Rimantadine / Q000627:therapeutic use; D014779:Virus Replication / Q000187:drug effects
D000577:Amides; D000998:Antiviral Agents; D002208:Caproates; D003998:Dicarboxylic Acids; D007093:Imidazoles; D012299:Rimantadine; D053139:Oseltamivir; C539419:pentanedioic acid imidazolyl ethanamide